TERRY MELVIN: Open Payments
NPI 1720191604 · CHATTANOOGA, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,448 in 73 payments from 22 companies in 2025. Trend: 2023 $786 · 2024 $1,269 · 2025 $1,448
Food & beverage: $1,448
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 9 | $160 |
| ABBVIE INC. | 12 | $158 |
| Xeris Pharmaceuticals, Inc. | 7 | $153 |
| Abbott Laboratories | 6 | $132 |
| Novo Nordisk Inc | 6 | $125 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $108 |
| Dexcom, Inc. | 3 | $78 |
| Tandem Diabetes Care, Inc. | 3 | $71 |
| Lilly USA, LLC | 4 | $65 |
| Sequel Med Tech, LLC | 2 | $58 |
Products named: LEQVIO, FREESTYLE LIBRE 3, Kerendia, RECORLEV, VRAYLAR, Rybelsus, Dexcom G6 Transmitter, t:slim X2 Insulin Pump with Control-IQ.
Industry payments across TN — which companies pay providers there.
